Groundbreaking Oncology Company Akamis Bio Secures $60 Million in Series A Funding

Akamis Bio, a pioneering clinical-stage oncology company, has successfully secured $60 million in a latest funding round aimed at advancing its innovative T-SIGn® platform. This substantial investment will significantly bolster Akamis’ mission to transform cancer treatment by harnessing the immune system’s ability to combat solid tumors. The company is at the forefront of developing a robust portfolio of T-SIGn® therapeutics, designed specifically to empower patients’ own immune cells to recognize, attack, and ultimately clear their cancerous cells. Central to their efforts is NG-350A, the lead program currently being investigated in an ongoing Phase 1 clinical study, targeting patients with metastatic or advanced epithelial tumors. This funding is not just a testament to Akamis' cutting-edge approach in oncology but also a critical enabler for the continued expansion of its T-SIGn® pipeline and furthering its collaborations with esteemed partners in the immuno-oncology space, including Bristol Myers Squibb (BMS), Merck, and the Parker Institute for Cancer Immunotherapy (PICI). With this new influx of capital, Akamis Bio is poised to accelerate its clinical development initiatives and potential launch new therapies that could significantly improve outcomes for patients battling cancer. As the company continues to innovate within the dynamic landscape of cancer treatment, it remains committed to making a meaningful impact on the lives of those affected by this formidable disease. To learn more about Akamis Bio and their groundbreaking work, visit www.akamisbio.com.